<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492440</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-107-04</org_study_id>
    <secondary_id>07-C-0114</secondary_id>
    <secondary_id>CLI-107-04</secondary_id>
    <nct_id>NCT00492440</nct_id>
  </id_info>
  <brief_title>Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase I Study of Subcutaneous &quot;CYT 107&quot; (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytheris SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cytheris, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cytheris SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in&#xD;
      treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of recombinant interleukin-7 (IL-7) in patients with metastatic&#xD;
           melanoma or locally advanced or metastatic renal cell carcinoma.&#xD;
&#xD;
        -  Confirm the previously documented safety profile of non-glycosylated IL-7 in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the safety of higher doses of recombinant IL-7 in these patients.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of recombinant IL-7 in these patients.&#xD;
&#xD;
        -  Determine the biologically active dose of recombinant IL-7 in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of recombinant IL-7 in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the biological and clinical effects of recombinant IL-7 with non-glycosylated&#xD;
           IL-7 in these patients.&#xD;
&#xD;
        -  Determine the potential antitumor effect of recombinant IL-7 in these patients.&#xD;
&#xD;
        -  Determine the dose and administration schedule of recombinant IL-7 in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are stratified according to lymphocyte&#xD;
      count (normal lymphocyte count [CD4+ T cells &gt; 400/mm^3] vs lymphopenic [CD4+ T cells &lt;&#xD;
      400/mm^3]). Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
        -  Group 1 (normal lymphocyte count): Patients receive recombinant interleukin-7 (IL-7)&#xD;
           subcutaneously once a week (to determine an active dose) for up to 3 weeks in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Group 2 (lymphopenic): Patients receive recombinant IL-7 subcutaneously once a week for&#xD;
           up to 3 weeks at one dose level below the active dose determined in group 1.&#xD;
&#xD;
      Cohorts of 3-6 patients from each group receive escalating doses of recombinant IL-7 until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is the defined as the dose preceding&#xD;
      that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 30&#xD;
      additional patients may be treated at the MTD.&#xD;
&#xD;
      Patients undergo blood and bone marrow collection periodically for pharmacokinetic,&#xD;
      pharmacodynamic, and immunological studies. Samples are analyzed for the presence of&#xD;
      antibodies and proteins via ELISA; CD3, CD4, and CD8 T cell counts, CD127, Ki-67, and Bcl-2&#xD;
      expression in CD4+ and CD8+ T cells, and CD19 B cell counts via flow cytometry; and clonal B&#xD;
      cell proliferation via PCR and flow cytometry.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of recombinant interleukin-7 (IL-7)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics of IL-7</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the biological and clinical effects of recombinant IL-7 with non glycosylated IL-7</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential antitumor effect of recombinant IL-7</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose and administration schedule of recombinant IL-7</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-7</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>CYT107 (r-hIL-7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Melanoma&#xD;
&#xD;
                    -  Metastatic disease&#xD;
&#xD;
               -  Renal cell carcinoma&#xD;
&#xD;
                    -  Locally advanced and unresectable disease OR metastatic disease&#xD;
&#xD;
          -  Refractory to standard therapy OR ineligible to receive standard therapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Previously received high-dose interleukin-2 OR have a contraindication for this&#xD;
             treatment&#xD;
&#xD;
          -  No previously untreated or unstable brain metastases&#xD;
&#xD;
          -  No splenic metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  PT/PTT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Conjugated (Direct) bilirubin ≤ 1.25 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  LVEF ≥ 45% by cardiac stress test (e.g., stress thallium, stress MUGA, dobutamine&#xD;
             echocardiogram, or other stress test) for patients meeting any of the following&#xD;
             criteria:&#xD;
&#xD;
               -  History of ECG abnormalities&#xD;
&#xD;
               -  Symptoms of cardiac ischemia&#xD;
&#xD;
               -  At least 50 years of age and over&#xD;
&#xD;
               -  Familial or personal history of heart failure&#xD;
&#xD;
               -  Previously treated with antimitotic agents susceptible to trigger heart failure&#xD;
&#xD;
          -  FEV_1 &gt; 60% of predicted (for patients with a prolonged smoking history or symptoms of&#xD;
             respiratory dysfunction)&#xD;
&#xD;
          -  No concurrent cognitive impairment or likelihood of developing cognitive impairment on&#xD;
             study therapy&#xD;
&#xD;
          -  No concurrent splenomegaly or proliferative hematologic disease&#xD;
&#xD;
          -  No documented HIV positivity&#xD;
&#xD;
          -  No acute hepatitis A or hepatitis B or C&#xD;
&#xD;
               -  Positive hepatitis B serology indicative of previous immunization (i.e., HBs Ab&#xD;
                  positive and HBc Ab negative) allowed&#xD;
&#xD;
               -  Positive hepatitis C serology allowed provided HCV RNA load by PCR is negative&#xD;
&#xD;
          -  Resting blood pressure ≤ 140/90 mm Hg on standard antihypertensive therapy&#xD;
&#xD;
               -  Untreated hypertensive patients who received standard antihypertensive therapy&#xD;
                  allowed provided hypertension is well controlled&#xD;
&#xD;
          -  No QTc prolongation ≥ 470 msec&#xD;
&#xD;
          -  No prior history of cardiovascular disease, arrhythmias, or significant ECG&#xD;
             abnormalities&#xD;
&#xD;
          -  No active infection requiring systemic treatment and/or hospitalization within the&#xD;
             past 28 days&#xD;
&#xD;
               -  Patients who have completed therapy or are clinically stable on therapy, in the&#xD;
                  opinion of the investigator, are eligible&#xD;
&#xD;
          -  No history of autoimmune disease&#xD;
&#xD;
          -  No history of severe asthma&#xD;
&#xD;
          -  No history of medical or psychiatric disease that would preclude study treatment&#xD;
&#xD;
          -  No documented cirrhosis or documented acute hepatitis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior systemic corticosteroid therapy&#xD;
&#xD;
          -  More than 4 weeks since prior and no other concurrent cytotoxic therapy,&#xD;
             immunotherapy, biological agents (i.e., cytokines, growth factors, or monoclonal&#xD;
             antibodies), or antitumor vaccines&#xD;
&#xD;
          -  More than 7 days since prior hepatotoxic drugs unless medically necessary&#xD;
&#xD;
          -  More than 2 days since prior alcohol consumption&#xD;
&#xD;
          -  More than 1 day since prior acetaminophen use&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No prior allogeneic hematopoietic stem cell transplantation or solid organ&#xD;
             transplantation&#xD;
&#xD;
          -  No concurrent palliative therapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent chronic anticoagulation (i.e., high-dose warfarin or heparin)&#xD;
&#xD;
               -  Warfarin dose 1 to 2 mg/day allowed&#xD;
&#xD;
          -  No concurrent chronic medications for asthma&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

